Effect of anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria

Effect of anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria - Anti-immunoglobulin E therapy on chronic prurigo and cholinergic urticaria

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028395

Enrollment

Registered

2017-09-01

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

urticarial dermatitis, prurigo, cholinergic urticaria

Interventions

Omalizumab 300mg/4weeks, 3times

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who are resistant to the treatments such as topical administration of steroid and orally administration of anti-histamine drugs

Exclusion criteria

Exclusion criteria: patients orally administrated immune suppressants or high-dose steroid within three months. patients suffering from severe visceral diseases and mental disorders patients who is pregnant or breast-feed patients judged inadequate to this study

Design outcomes

Primary

Measure	Time frame
skin symptom blood check subjective symptom	—

Countries

Japan

Contacts

Public ContactTsukasa Ugajin

Tokyo Medical and Dental University Department of Dermatology

ugajin.derm@tmd.ac.jp03-5803-5286

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026